Crestor
Asked that manufacturers Crestor ceased to publish ad targeted on patient sent the letter to Astra Zeneca in 21-y December, speaking that this was concerned about that ad to can to play well together downwards risk bound Crestor.
spokesperson For AstraZeneca reported ad was one. He has added that ad not anymore anyway. He has persisted to Crestor such safe as any other statin.
Crestor Contains the medicine rosuvastatin, which belongs to the group a medicine heard as HMG-CoA reductase inhibitors, or ’statins.
Crestor is Used to modify the emergency level fat substance on blood named lipids, mainly high level of the cholesterol and triglycerides. Crestor is Used in combinations with plan of the diet when change on diet and exercise only did not reduce the high cholesterol and triglycerides.
Rosuvastatin Belongs to the group a medicine heard as HMG-CoA reductase inhibitors, or ’statins.
– HMG-CoA reductase, - an enzyme (chemical) in tele what transformations 3-hydroxy-3-methylglutaryl coenzyme to mevalonate, which - then transformed in cholesterol.
– Brake HMG-CoA reductase, Crestor reduces the general amount of the cholesterol made by body.
– There is 2 types of the cholesterol on shelters, cholesterol LDL- (”Bad Cholesterol”) and cholesterol HDL- (”Good cholesterol”)
– Brake HMG-CoA reductase, results Crestor in more low level (”Bad”) cholesterol LDL-and reduces triglycerides on shelters.
CRESTOR ALSO on raised level (”Well”) cholesterol HDL-on shelters.
Crestor Available as as soon as day tablet, which can be given anytime day and can be will take with or without the food.
Astrazeneca Declared start the new clinical test, SATURN, designed to measure the influence CRESTOR (rosuvastatin) 40 mg. and Lipitor (atorvastatin) 80 mg. in passing on high patient of the risk. THE SATURN confer the effects these two statins on abilities to reduce the passing or generate the regression the main reason cardiovascular disease, the following two years of the processing on patient with disease of the coronary artery.
Dr George Kassianos, GP, Bracknell and Lad European Society to Cardiologies commented: ” announcement of this head main analysis between rosuvastatin and atorvastatin agitates the news to as this for the first time addresses important clinical and scientific questions by direct comparison. THE SATURN of the analysis will provide the by best understanding effect these two well installed statin processing on patient with leading and as to address them accordingly.”
THE SATURN, (the Study Coronary Atheroma Ultrasound InTravascular: Effect Rosuvastatin Against AtorvastatiN), - 104- week, parallel-group, multicentre, double-blind, Phase IIIb intravascular ultrasound (IVUS) visualizing study aproximately 1,300 patients in 170 centres worldwide. The First patient will be enrolled following this month and analysis is expected terminate in 2011. THE SATURN - a part of extended clinical test the GALAXY AstraZeneca’s programme, to address the important unanswered questions in statin study and to research the influence rosuvastatin on management lipids, and heartily morbidity and mortality. Currently, more, than 63,000 patients with 55 countries worldwide to participate in Program of the GALAXY.
Elisabeth Bjork, Global Medical Director of the Science for CRESTOR commented: “Two specialize the studies in program of the GALAXY have already demonstrated the significant influence CRESTOR 40mg in through spectrum disease. The Analysis of the ASTEROID was first to show the regression coronary on patient with installed by disease, and analysis of the METEOR shown that CRESTOR can also slow or delay the passing carotid on patient with early sign disease. Results of the SATURN of the analysis will provide additional information on as to the best advantage to process patient with leading
CRESTOR has NOW got the plenipotentiary approvals in over 90 countries. Over 11 million patient, is given CRESTOR worldwide.
New given presented today in National Medical Assotiation Hispanic (NHMA) annual meeting shown that AstraZeneca’s CRESTOR(R) (rosuvastatin calcium) in 10 and 20 mg reduced LDL-C or cholesterol “bad” to 45.2 and 50.0 percent, in contrast with 35.9 and 42.4 percent with atorvastatin in dose on patient Hispanic with elevated cholesterol (p<0.017 vs of the dose atorvastatin). THE INTERSTELLAR nave (STUDY to Value Rosuvastatin in Population HIspanic), - first-ever large-scale, expected test solely designed to compare the effects statins on patient Hispanic, who usually underrepresented in clinical test.
“INTERSTELLAR nave is a first test to demonstrate vastly greater efficiency in, reducing cholesterol LDL-on patient Hispanic, used of the dose of the milligramme CRESTOR in contrast with atorvastatin,” said Dr. Ramon Lloret, leaden investigator STARSHIP and president of the Cardiovascular Centre of the South Florida in Miami. “As physician Hispanic, which processes this on traditions underserved population, I see the firsthand importance this analysis. Test the INTERSTELLAR nave presents the important possibility to demonstrate efficiency and safety statins in this population.”
THE INTERSTELLAR nave was a poles week, mixed, operated, openning-label, much-test the centre designed to value efficiency CRESTOR and atorvastatin on patient Hispanic with elevated cholesterol. After poles week dietetic lead- in, 696 adult Hispanic mainly average and high risk patient as defined managing principle NCEP ATP III, with historian of the coronary heart disease (CHD), equivalent of the risk CHD, or 10-risk vrem)g. event Framingham CHD equal or more, than 10 percents, were mixed on one of four opened labels of the processing during poles week: CRESTOR 10 or 20 mg. or atorvastatin 10 or 20 mg. The General safe experience was similar for all processing in analysis of the INTERSTELLAR nave.
Additional given with INTERSTELLAR nave demonstrated:
- General cholesterol reduction to 32.4 and 34.9 percent with CRESTOR 10 and 20 mg. in contrast with 25.6 and 30.9 percent for atorvastatin 10 and 20 mg. (p<0.017 vs of the dose atorvastatin)
- Reduction ne-hdl-C to 40.9 and 44.6 percent with CRESTOR 10 and 20 mg. in contrast with 32.6 and 39.2 percent for atorvastatin in same dosage (vs milligramme p<0.017 of the dose atorvastatin)
- Increase HDL-C to 5.5 and 5.7 percent with CRESTOR in 10 and 20 mg. in contrast with 3.5 and 4.3 percent with atorvastatin in dose
These given also were recently presented in American College of the Cardiologies (ACC) of the annual meeting. Under-analysis with INTERSTELLAR nave, in reactive protein C- (CRP) was recently submitted for 46-y Annual Conference in Cardiovascular Epidemoloshii Disease and Preventions with Advice in Feeding, Physical Activity, and Metabolism subsidized the American Warmhearted Assotiation and found that CRESTOR reduced the level CRP from baseline. These results shown 18.8 and 26.7 percent of the reduction on level median CRP with CRESTOR 10 and 20 mg. in contrast with 16.8 and 23.8 percent of the reduction with atorvastatin in dose milligramme (vs. the baseline p<0.01). CRP - a protein in tele, which - not-specific marker of the inflammation.
